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ABSTRACT.
Purpose: Uncorrected refractive errors are the first cause of vision impairment worldwide. High myopia is a frequent cause
of sight-threatening chorioretinal complications. The aim of this study was to evaluate the prevalence of macular
complications, visual impairment and blindness in patients with myopia.
Methods: A cross-sectional multicenter study carried out in French eye clinics mainly dedicated to refractive errors.
Myopia severity was defined as mild (0.5 to 3 D), moderate (3 to 6 D), high (6 to 10 D) and very high (more than
10 D). Macular complications related to myopia included lacquer cracks, myopic choroidal neovascularization,
chorioretinal atrophy and retinoschisis. The prevalences of macular complications, blindness and vision impairment were
estimated with respect to degree of myopia and age. Eligibility criteria were myopia on the left eye of 0.5 D or more.
Exclusion criteria included any missing data related to subjective refractive error, age, gender and any history of cataract
or refractive surgery.
Results: Data files from 198 641 myopic individuals with a mean age of 34 years (SD: 15 years) were analysed. The
prevalence of mild, moderate, high and very high myopia was, respectively, 65.95%, 26.14%, 6.72% and 1.19%. The
prevalence of macular complications in the high and very high myopia groups was 0.5% [0.39–0.64] and 4.27% [3.49–5.17].
The prevalence of blindness or vision impairment was observed in 10.10% [8.91–11.39%] of the very high myopic group. At
60 years old or over, the prevalences of blindness or vision impairment were, respectively, 9.75% [7.91–11.85%] and
25.71% [21.00–30.87%] in the high and very high myopia groups.
Conclusions: This multicenter cross-sectional study provides new insights in terms of prevalence of macular complications
related to myopia. To our knowledge, this is one of the largest European studies focusing on individuals with myopia,
particularly on the macular complications and the functional consequences in relation to myopia.
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Introduction
In 2000, according to deﬁnitions of
myopia and high myopia by refractive
error of 0.50 and 5 dioptres (D) or
more, myopia and high myopia were
estimated to aﬀect 1.406 billion people
(22.9%) and 163 million people (2.7%)
in the world, respectively. In the same
study, projections estimated that by
2050, the prevalence ofmyopia and high
myopia will aﬀect nearly 4.7 billion
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people and 1 billion people, respectively
(Holden et al. 2016). The rise in preva-
lence has been documented extensively
among young urban Asian populations,
yet other populations are also concerned
by the myopia epidemic. Indeed,
between 1999 and 2004, the prevalence
of myopia (deﬁned by refractive error
≤1D) in the United States among
individuals aged 20 years or older rose
from 20.5% to 36.2% (Vitale et al.
2008). From six studies providing
refractive data on 29 281 individuals
aged 40 years or older living in the US,
Western Europe and Australia, the Eye
Diseases Prevalence Research Group
reported estimated prevalences of myo-
pia (deﬁnedby refractive error≤1D)of
25.4%, 26.6% and 16.4%, respectively
(Kempen et al. 2004).
In parallel, the prevalence of high
myopia, usually deﬁned as 5 or more
or 6 dioptres or more of myopia, has
increased, with prevalences approxi-
mating 20% in some young Asian
populations (Lin et al. 2004; Koh et al.
2014).
Myopic maculopathy is a major
cause of vision impairment worldwide.
This spectrum of macular disorders
usually associated with high and patho-
logic myopia frequently aﬀects individ-
uals at working age. In the Taizhou
Eye Study conducted in China (2012–
2013), myopic macular degeneration
was the second cause of vision impair-
ment in adults aged 45–59 years after
cataract (Tang et al. 2015). In Japan,
myopic maculopathy is also a major
cause of blindness and vision impair-
ment in persons aged over 40 years
(Iwase et al. 2006). In the United
States, Western Europe and Australia,
macular degeneration, including age-
related macular degeneration (AMD)
and myopic macular degeneration, is
the major cause of blindness (Bourne
et al. 2014).
Given a pandemic level of myopia, it
is very likely that vision impairment
related to myopic maculopathy will
increase, with subsequent repercussions
on socio-economic cost, quality of life
and working eﬃciency (Saw et al.
2005). Furthermore, the burden of
myopic maculopathy in terms of dis-
ability-adjusted life years (DALYs) is
probably much higher than AMD, the
ﬁrst cause of vision impairment in
developed countries, due to the age at
occurrence of macular complications in
high myopia. Indeed, lacquer cracks or
myopic choroidal neovascularization
frequently occur at around ﬁfty years
of age (Wolf et al. 2014; Ikuno et al.
2015), chorioretinal atrophy usually
being the last stage of myopic macu-
lopathy.
While many studies have focused on
the prevalence of myopia itself and its
consequence in terms of functional
impact, the prevalence of macular com-
plications of myopia and the functional
consequences remain largely unknown.
In this context, we aimed to describe
the prevalence of macular complica-
tions related to myopia and their visual
impact in a large group of European
individuals through a cross-sectional
study.
Materials and Methods
Study design
This cross-sectional study was carried
out in French eye clinics mainly dedi-
cated to refractive errors.
Data collection
Data collection included age, gender,
subjective refractive error, visual acuity,
any relevant medical history such as
laser refractive surgery, cataract surgery
and any macular complications related
to myopia on both eyes. Best-corrected
visual acuity was assessed on aMonoyer
chart and determined after objective
auto-refractometry followed by subjec-
tive reﬁnement. All individuals under-
went an ophthalmic examination,
including non-cycloplegic autorefrac-
tion on both eyes in adults (tono-refrac-
tometer, Nidek) and cycloplegic
autorefraction with cyclopentolate for
children, a slit-lamp examination and a
fundus examination.
The assessment of any macular com-
plication related to myopia was made
by an ophthalmologist, based on col-
our fundus images, auto-ﬂuorescence,
SD-OCT scans and ﬂuorescein and
indocyanin angiography if judged nec-
essary by the physician himself.
Because grading of chorioretinal
atrophy can be diﬃcult in myopia,
due to thinner choroid with maintained
normal visual acuity, we only consid-
ered macular chorioretinal atrophy
when the presence of patchy chorioreti-
nal macular atrophy or macular atro-
phy was clearly mentioned in the data
ﬁle.
Refractive and examination data
Severity of myopia was classiﬁed as
mild myopia (0.5 to 2.75 D), mod-
erate myopia (3 to 5.75 D), high
myopia (6 to 9.75 D) and very high
myopia (more than 10 D).
Macular complications related to
myopia included lacquer cracks, past
or active myopic choroidal neovascu-
larization, chorioretinal atrophy and
retinoschisis. Staphyloma was consid-
ered as an anatomical particularity of
myopia rather than a complication.
These diﬀerent lesions were assessed
by fundus examination, spectral
domain optical coherence tomography
(SD-OCT) and ﬂuorescein angiogra-
phy if judged necessary by the oph-
thalmologist.
Exclusion criteria included any miss-
ing data related to subjective refractive
error, age, gender, and any history of
refractive or cataract surgery.
Vision impairment was deﬁned using
visual acuity (VA) for the better eye
strictly less than 0.5–0.05 included.
Blindness was deﬁned as VA for the
better eye strictly less than 0.05,
according to the World Health Orga-
nization criteria.
Data collection was declared to the
Commission nationale de
l’informatique et des libertes (CNIL).
The described research adhered to the
tenets of the Declaration of Helsinki.
Data annotation
The original data set contained the
records of 602 103 myopic and non-
myopic patients.
In the initial database, information
pertaining to complications and exclu-
sion criteria was part of unstructured
text ﬁelds. Patient annotation for a
given complication was carried out
through a three-step text-mining pro-
cess:
• Extraction of relevant terms from all
text ﬁelds
• Selection of records based on these
terms (47 438 records)
• Manual review and annotation of
the selected records
Statistical analysis
A complication was assigned to a
patient as opposed to an eye, that is
regardless of whether the right or left
eye was mentioned, it was considered
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present. Similarly, a patient was given
visual acuity status (‘no vision impair-
ment’, ‘vision impairment’ or ‘blind-
ness’) based on the better eye.
Refractive errors (REs), on the other
hand, were assigned to an eye. Only left
eyes were considered in the analysis for
RE, making the common assumption
that both eyes are highly correlated.
Refractive errors were quantiﬁed by
the sphere instead of the spherical
equivalent.
The prevalence of vision impairment
and blindness, and the prevalences of
complications were computed with
respect to myopia severity, age, and
gender, and reported with exact Clop-
per–Pearson binomial 95% conﬁdence
intervals (CI).
Univariate and multivariate odds
ratio (OR) for myopia severity were
computed from logistic regression coef-
ﬁcients with corresponding Wald 95%
CI.
The probability of macular compli-
cations as a function of the sphere was
modelled using logistic regression, con-
trolling for age and sex. Patients with
sphere smaller than 17D were
excluded because of low sample size.
Model ﬁt was checked using the Hos-
mer and Lemeshow test.
All analyses were performed with
SAS/STAT software, version 9.4 of the
SAS System for Windows. Copyright ©
2016 by SAS Institute Inc.
Results
Demographic and refractive data
Data from 198 641 myopic patients
(mean age 34  15 years) were
included in the analysis. The distribu-
tion of severity of myopia in this
population was mild 65.95%, moderate
26.14%, high 6.72% and very high
1.19%. Demographic and refractive
data are presented in Table 1.
Macular complications
In terms of macular complications, the
prevalence of lacquer cracks (LC) and
myopic choroidal neovascularization
(mCNV) was, respectively, 0.07%
[0.03–0.13%] and 0.07% [0.03–0.13%]
in the high myopia group, whereas
these frequencies were 0.51% [0.26–
0.88%] and 0.42% [0.20–0.78%]) in the
very high myopia group. The preva-
lence of chorioretinal atrophy (CRA)
was 0.39% [0.29–0.51%] and 3.42%
[2.73–4.24] in the high and very high
myopia groups, respectively. Similarly,
the prevalence of retinoschisis was
0.03% [0.01–0.08%] and 0.30% [0.12–
0.61%]. These results are detailed in
Table 2.
A signiﬁcant increase in the preva-
lence of macular complications in rela-
tion to the severity of myopia was
observed. After correcting on age and
gender, the probability of any macular
complication depends exponentially on
the sphere, with odds ratio for a unit
dioptre decrease equal to 1.43 [1.40–
1.47]. In other words, a decrease by one
dioptre results in a risk multiplied by
1.43, age and sex remaining equal
(Fig. 1).
Taking mild myopia as the reference
group, univariate ORs for lacquer
cracks were 29.45 [7.97–108.78] and
223.69 [62.80–789.65] in the high myo-
pia and very high myopia groups.
Similarly, the ORs for myopic choroi-
dal neovascularization were 17.67
[5.92–52.73] and 111.25 [38.00–
325.73], respectively. Considering
chorioretinal atrophy, risk was associ-
ated with an odds ratio of 11.63 [7.78–
17.39]) and 105.55 [72.95–152.72] in the
high myopia and very high myopia
groups, respectively.
After adjustment for age and gender,
multivariate logistic regression analysis
showed that risk of lacquer cracks was
associated with ORs of 29.09 [7.86–
107.64] and 158.45 [44.39–565.51] in
the high myopia and very high myopia
groups, respectively. Similarly, the ORs
for myopic choroidal neovasculariza-
tion were 17.00 [5.68–50.87] and 70.60
[23.98–208.85]. Considering chorioreti-
nal atrophy, risk was associated with
an odds ratio of 11.66 [7.78–17.46] and
74.08 [50.94–107.75] in the high myopia
and very high myopia groups. These
results are detailed in Table 2, while
the prevalence of macular complica-
tions depending on age and myopia
severity is presented in Figure 2.
Functional impact
Vision impairment and blindness were
observed in 0.54% [0.51–0.57%] and
0.53% [0.50–0.56%], respectively, of
the myopic population. In the high
myopia group, frequencies of vision
impairment and blindness were 1.21%
[1.03–1.41%] and 0.44% [0.34–0.57%],
respectively, whereas these frequencies
were 8.44% [7.34–9.63%], and 1.66%
[1.18–2.26%]) in the very high myopia
group.
Subgroup analyses of vision impair-
ment and blindness were also
Table 1. Age, refraction and functional data according to gender and myopia severity
N (%)
Age
Mean  SD
Sphere
Mean  SD
Visual impairment
% [95% CI]
Blindness
% [95% CI]
Visual impairment
or blindness
% [95% CI]
Myopes 198 641 (100.00) 34  15 2.63  2.21 0.54 [0.51–0.57] 0.53 [0.50–0.56] 1.07 [1.02–1.11]
Gender
Females 110 777 (55.77) 34  15 2.73  2.29 0.55 [0.50–0.59] 0.52 [0.48–0.56] 1.06 [1.00–1.12]
Males 87 864 (44.23) 35  15 2.50  2.10 0.53 [0.48–0.58] 0.54 [0.49–0.59] 1.07 [1.00–1.14]
Myopia class
Mild myopia 131 001 (65.95) 34  15 1.41  0.70 0.37 [0.33–0.40] 0.53 [0.49–0.57] 0.89 [0.84–0.95]
Moderate myopia 51 920 (26.14) 35  14 4.05  0.82 0.45 [0.39–0.51] 0.49 [0.43–0.56] 0.94 [0.86–1.03]
High myopia 13 355 (6.72) 36  14 7.20  1.03 1.21 [1.03–1.41] 0.44 [0.34–0.57] 1.65 [1.44–1.88]
Very high myopia 2365 (1.19) 41  15 13.00  3.31 8.44 [7.34–9.63] 1.66 [1.18–2.26] 10.10 [8.91–11.39]
Myopia severity in the left eye was deﬁned as mild (0.5 to 3 D), moderate (3 to 6 D), high (6 to 10 D) and very high (more than 10 D).
Vision impairment and blindness were deﬁned as best-corrected visual acuity (VA) for the better eye strictly less than 0.5–0.05 included and strictly
less than 0.05, respectively.
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performed by deﬁning three subgroups
categorized by the 0–29 years, 30–
59 years and 60 years old or more
groups. In the 30–59 years age group,
the prevalences of blindness or vision
impairment were 1.02% [0.80–1.29%]
and 8.29% [6.87–9.89%], respectively,
in the high and very high myopia
groups. In the 60 years old or more
age group, the prevalences of blindness
or vision impairment were 9.75%
[7.91–11.85%] and 25.71% [21.00–
30.87%], respectively. These results
are detailed in Fig. 2.
Discussion
The main objective of the present study
was to investigate the macular compli-
cations of myopia and associated vision
impairment in a large group of individ-
uals. In this group of individuals with a
mean age of 34 years, vision impairment
or blindness was observed in 1.65%
[1.44–1.88] and 10.10% [8.91–11.39] of
high and very high myopic patients
(Table 1). These results, for a rather
young group of European patients,
obviously raised the question of visual
impact of myopia in older populations
and in populations with a higher inci-
dence of high myopia. This concern is
conﬁrmed by the fact that of all the
persons with high myopia and very high
myopia reported in this study, 9.75%
[7.91–11.85%] and 25.71% [21.00–
30.87%], respectively, had developed
vision impairment or blindness by the
age of 60.
Literature data
These results are corroborated by
Tideman et al. In a cross-sectional
study based on 15 693 Europeans
drawn from population-based data in
the Rotterdam Study I to III, the
Erasmus Rucphen Family Study and
from case–control data in the Myopia
Study, all of them from the
Netherlands, the cumulative risk of
vision impairment (best-corrected VA
in the right eye strictly less than 0.3–
0.05 included) by age 75 years was
20.0% for 6 to greater than 10 D,
19.9% for 10 to greater than 15 D,
and 80.3% for 15 D or less (Tideman
et al. 2016).
In a Scandinavian study including
10 135 participants randomly selected
by the Copenhagen central population
registry from a prospective cardiovascu-
lar population-based study, myopia-re-
lated retinal disorders accounted for 7%
of the causes of vision impairment (best-
correctedVAin thebettereyeworse than
0.5 and better than 0.01) and for 14% of
causes of blindness (best-corrected VA
in thebetter eye equal to0.01orworse) in
the total study population. However,
between 20 and 64 years of age,myopia-
related retinal disorders accounted for
26% of the causes of vision impairment
and for 14% of the causes of blindness
(Buch et al. 2004).
Previously, the Rotterdam study
showed that myopic degeneration was
a major cause of vision impairment in
subjects younger than 75 years (Klaver
et al. 1998).
In a Chinese population-based
cohort study including 10 234 partici-
pants aged 45 years or more, the ﬁrst
cause of total bilateral and monocular
vision impairment among adults 45–
59 years of age was myopic macular
degeneration in 59.6% and 27.2%,
respectively (Tang et al. 2015). In other
studies on Chinese populations, the
Beijing Eye Study and the Shihpai
Taiwan Eye Study, myopic macular
degeneration accounted for 32.7% of
low vision and 12.5% of vision
Table 2. Prevalence of staphyloma and macular complications, and odds ratios, with respect to myopia severity
Mild myopia (N = 131 001) Moderate myopia (N = 51 920) High myopia (N = 13 355) Very high myopia (N = 2365)
Staphyloma N, % [95% CI] 136 0.10 [0.09–0.12] 260 0.50 [0.44–0.57] 269 2.01 [1.78–2.27] 181 7.65 [6.61–8.80]
OR [95% CI] Reference 4.94 [4.02–6.09] 19.42 [15.78–23.90] 63.95 [50.85–80.43]
Macular
complications
N, % [95% CI] 56 0.04 [0.03–0.06] 72 0.14 [0.11–0.17] 67 0.50 [0.39–0.64] 101 4.27 [3.49–5.17]
OR [95% CI] Reference 3.43 [2.42–4.87] 11.72 [8.20–16.75] 74.31 [53.20–103.79]
Chorioretinal
atrophy
N, % [95% CI] 44 0.03 [0.02–0.05] 57 0.11 [0.08–0.14] 52 0.39 [0.29–0.51] 81 3.42 [2.73–4.24]
OR [95% CI] Reference 3.48 [2.35–5.17] 11.66 [7.78–17.46] 74.08 [50.94–107.75]
Lacquer cracks N, % [95% CI] 3 0.00 [0.00–0.01] 4 0.01 [0.00–0.02] 9 0.07 [0.03–0.13] 12 0.51 [0.26–0.88]
OR [95% CI] Reference 3.52 [0.79–15.76] 29.09 [7.86–107.64] 158 [44.39–565.51]
Myopic choroidal
neovascularization
N, % [95% CI] 5 0.00 [0.00–0.01] 6 0.01 [0.00–0.03] 9 0.07 [0.03–0.13] 10 0.42 [0.20–0.78]
OR [95% CI] Reference 3.14 [0.96–10.32] 17.00 [5.68–50.90] 70.60 [23.98–207.85]
Retinoschisis N, % [95% CI] 7 0.01 [0.00–0.01] 9 0.02 [0.01–0.03] 4 0.03 [0.01–0.08] 7 0.30 [0.12–0.61]
OR [95% CI] Reference 3.29 [1.22–8.84] 5.37 [1.57–18.35] 40.56 [14.07–116.90]
Odds ratios (adjusted for age and gender) of moderate, high and very high myopia for the occurrence of complications were computed with logistic
regression and use mild myopia as reference. Myopia severity in the left eye was deﬁned as mild (0.5 to 3 D), moderate (3 to 6 D), high (6 to
10 D) and very high (more than 10 D).
Fig. 1. Logistic model of the risk to present macular complications with respect to myopia degree.
Macular complications include lacquer cracks, myopic choroidal neovascularization, chorioretinal
atrophy and retinoschisis. Myopia severity in the left eye was deﬁned as mild (0.5 to 3 D),
moderate (3 to 6 D), high (6 to 10 D) and very high (more than 10 D).
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impairment, respectively (Hsu et al.
2004; Xu et al. 2006).
Even if clearly demonstrated, the
precise relationship between degree of
myopia and risk of developing macular
complications remains to be clariﬁed.
There may be a relationship with
increased risk of complications for each
unit increase in spherical equivalent in
dioptres and/or unit increase in axial
length in millimetres and a threshold
beyond which the risks of complica-
tions increase exponentially after a
certain level of refractive error.19 In
the current study, due to large sample
size, we observed that the risk of
macular complication increased expo-
nentially with myopia degree.
Myopia and vision impairment
Overall vision impairment due to myo-
pia obviously combines both refractive
error itself and disabilities due to ocular
complications which mainly include
cataract, glaucoma, macular complica-
tions and retinal detachment. It is likely
that the burden of uncorrected refrac-
tive error itself represents the main part
of DALYs related to myopia in coun-
tries with a low socio-economic level,
whereas complications of myopia are
likely to represent the main part of
DALYs in developed countries where
access to optical corrections by lenses,
glasses or by refractive surgery is more
widely available. Interestingly, in a sys-
tematic review based on surveillance of
the prevalence and causes of vision
impairment in high-income countries
and Central/Eastern Europe, uncor-
rected refractive error was the leading
cause of moderate and severe vision
impairment deﬁned by visual acuity in
the better eye of worse than 6/18 to 3/60
inclusive, contributing to almost half of
the vision impairment burden (Bourne
et al. 2018).
Limitations
We acknowledge some limitations of
this study. Although the sample size
was large, caution should be taken in
interpretation of the frequencies
reported in this study, because this
was a clinic-based sample mainly serv-
ing people with refractive errors, and
therefore is not necessarily representa-
tive of what would be found in the
general population. Diﬀerences
between clinic-based and population-
based ﬁndings may be less notable
when considering those aged 50 years
or more in our sample as a higher
proportion of the population in this
age is likely to seek optometric assess-
ment for reasons of presbyopia.
Patients with a history of cataract or
refractive surgery were excluded
because their refractive status prior to
surgery was unknown. Since 1934
patients (0.97%) were in this situation,
these exclusions may have slightly
lowered the overall frequency of vision
impairment.
Furthermore, while the cross-sec-
tional design of this study provided
much information on the visual func-
tion and macular complications at a
given time, the temporal sequence of
Fig. 2. Prevalences of macular complications, vision impairment and blindness depending on age and myopia severity. Macular complications include
lacquer cracks, myopic choroidal neovascularization, chorioretinal atrophy and retinoschisis. Myopia severity in the left eye was deﬁned as mild (0.5
to 3 D), moderate (3 to 6 D), high (6 to 10 D) and very high (more than 10 D). Vision impairment and blindness were deﬁned as best-
corrected visual acuity (VA) for the better eye strictly less than 0.5–0.05 included and strictly less than 0.05, respectively.
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the macular complications cannot be
determined by this approach. In the
same way, myopic eyes with vision
impairment are frequently prone to
have several macular complications,
so that it is not possible to be abso-
lutely conﬁdent of the principal con-
tributing factor to vision impairment.
For this reason, we did not attempt to
correlate any particular macular com-
plications to visual function.
The international photographic clas-
siﬁcation and grading system of myo-
pic maculopathy according to the
META-analysis for Pathologic Myopia
study group deﬁned ﬁve categories of
myopic maculopathy, including no
myopic retinal change (category 0),
tessellated fundus (category 1), diﬀuse
chorioretinal atrophy (category 2),
patchy atrophy (category 3) and mac-
ular atrophy (category 4) with addi-
tional features deﬁned as ‘plus’ lesions
(lacquer cracks, myopic choroidal neo-
vascularization and Fuchs spot)
(Ohno-Matsui et al. 2015). The current
study only focused on the last two
categories of chorioretinal atrophy and
did not consider tessellated fundus or
diﬀuse atrophy because these two
forms of atrophy, according to the
study design, were considered as less
clinically relevant under the scope of
vision impairment and blindness than
the other two, more advanced forms of
atrophy.
The choice of a classiﬁcation of
myopia according to the degree of
refractive error can also be challenged,
because it has been clearly demon-
strated that no safe threshold for
myopic refractive errors exists. Indeed,
macular complications of myopia are
frequently observed even below 6 D
in absolute value (Flitcroft 2012). We
chose to follow a convention of cate-
gorizing myopes by refractive error
magnitude in common with many
other studies. It may also be objected
that pathologic macular changes are
better correlate with axial length than
with refractive errors. However, the
current data reﬂect the daily ophthal-
mological practice of French ophthal-
mologists and axial length
measurements are not currently recom-
mended for usual follow-up of myopic
patients. Furthermore, it has been
shown that although slightly lower
cumulative risks of visual impairment
in myopia are observed when using
refractive data, the trends are similar
when using axial length (Tideman et al.
2016).
Myopia and strategies to deal with it
Myopia has been deﬁned as one of the
ﬁve immediate priorities for the
‘Vision 2020’ initiative by the World
Health Organization because it is a
major cause of vision impairment in
populations throughout the world
(Pararajasegaram 1999). In this con-
text, two complementary approaches
are needed. It is of crucial importance
to investigate more precisely the
impact of all potential complications
of myopia on visual acuity on targeted
populations. The present study
focused on the macular complications
of myopia and not on other ocular
complications related to high myopia,
such as cataract, optic neuropathy and
retinal detachment, which are fre-
quently associated with myopic macu-
lopathy. Analyses of the data
speciﬁcally related to retinal detach-
ment and glaucoma are ongoing.
Secondly, given the global increase
of myopia and high myopia, there is a
need to develop nationwide preventive
strategies. Some Asian countries con-
fronted with the highest myopia inci-
dence are developing such strategies,
based on environmental, pharmaco-
logic and optical approaches targeting
the two pathways for myopia control:
slowing the onset of myopia and reduc-
ing or preventing progression. For
example, it has been demonstrated that
longer outdoor time can be of beneﬁt
on myopia onset but not on myopia
progression (Jones-Jordan et al. 2012;
French et al. 2013).
Comparison of studies aiming to
evaluate the impact of near-work activ-
ities on myopia is a challenge since
near-work activities (such as studying,
reading, computer use or watching TV)
are diversely deﬁned and because stud-
ies have reported highly diﬀerent out-
comes regarding progression of
myopia. While some studies conclude
that near-work activities are a risk
factor, others do not (Wu et al. 2010,
2015; Lee et al. 2015).
In a systematic review and meta-
analysis, association between near-
work activities and myopia indicated
a 2% increase in the odds of myopia
occurrence per additional dioptre-hour
of time spent on near work per week
(Huang et al. 2015).
Children treated by atropine 0.01%
have lower myopia progression with
minimal myopic rebound after atropine
is stopped and present negligible eﬀects
on accommodation, pupil size and near
visual acuity (Chia et al. 2012, 2014,
2016). Its mechanism of action remains
to be speciﬁed.
Orthokeratology uses reverse geom-
etry lenses worn overnight to tem-
porarily ﬂatten the corneal centre and
to provide a peripheral myopic defo-
cus. A meta-analysis including 7 stud-
ies showed that this approach results
in 45% reduction of myopia progres-
sion at 2 years (Sun et al. 2015).
However, its indications must be dis-
cussed for each case according to the
degree of myopia (mild or moderate),
risk of discomfort and microbial ker-
atitis.
Other therapeutic strategies to slow
down myopia progression have been
evaluated: undercorrection of myopia
is not eﬀective and may potentially be
harmful (Chung et al. 2002), and rigid
gas oxygen-permeable lenses do not
slow myopia progression (Katz et al.
2003).While many approaches aimed at
decreasing myopia progression pre-
sently exist, there remains a need to
deﬁne precisely preventive personalized
protocols for each myopic patient,
depending mainly on degree of myopia,
age and socio-economic integration.
In summary, this is to our knowl-
edge the widest survey of prevalence of
myopia in Europe aiming to investigate
macular complications and their visual
impact. We hope that the sight-threat-
ening impact of myopia will lead to
future therapeutic personalized proto-
cols stratiﬁed by age group and degree
of myopia.
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